Choosing the Right Drug Name How to Increase Your Chances for Approval
Product Details
The FDA can shut down your next promising product due to nothing more than a single letter of its name. They already reject 40% of proposed drug names. How can you up your odds?
You’ve invested in the bench science, locked down the clinical trial data and have pulled together the application ― all you need now is a hot product name.
But that should be a snap. Consult a Latin dictionary, hold an employee naming contest, convene a brainstorming session ... you’ll have your new name in three, four months tops.
Right?
Wrong, wrong, wrong. In truth, such methods are recipes for disaster, says brand consultant Jeff Gregory. He ought to know. He was in on the naming of Viagra®, Epogen®, Ambien®, Restasis® and many other blockbuster drugs.
Order this audio CD/Transcript, where Gregory took 90 minutes out of his busy schedule to initiate you into the secrets of drug-naming.
You’ll discover:
- How one wrong letter can trigger FDA action, adding years and millions of extra dollars in expenses to your product launch
- Why naming contests and brainstorming can actually lead to spending more on drug-naming consultants
- The top 5 deal-killers in drug naming ― and how to steer clear of them
- How close you can come to the line ― without crossing it ― in descriptive and benefit-driven drug naming
- What to not even consider in drug naming
Gregory will debunk the urban legends about what brand names really mean ... how the X, Y and Z craze began ... how to position a brand in terms of the target audience, not the science ... and that’s just the beginning. You’ll learn:
- Best practices for approaching a brand-name development project
- Why the last FDA nomenclature director got the nickname Dr. Boring
- Latest news from the FDA’s Proprietary Name Pilot Program
- And why drug naming is so much harder than it looks
There are reasons that savvy drug and biologic companies spend $1 million ... $2 million ... even $3 million naming a new drug ... why they bring naming consultants on board at the earliest stages of clinical testing ... why the FDA rejects 40% of proposed drug names each year.
It costs you millions when the FDA delays your launch campaign. That’s not a risk worth taking — especially when you can pick the brain of one of the brainiest drug-namers around. Because it’s web-based, this 90-minute session is totally interactive — meaning you get your every question answered by the time you log off.